Navigation Links
CRF announces featured clinical trials to be presented at TCT 2010
Date:8/12/2010

NEW YORK, NY August 12, 2010 The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 25 in Washington, DC.

Data from these trials are expected to influence the practice of interventional cardiovascular medicine and have an immediate impact on guidelines and patient care. These featured trials will be highlighted during sessions throughout TCT.

TUESDAY, SEPTEMBER 21, 6:00 PM 7:45 PM

  • SYNTAX Left Main: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Left Main Coronary Artery Disease
  • SYNTAX 3VD: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Triple Vessel Coronary Artery Disease
  • EXECUTIVE: A Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Multivessel Coronary Artery Disease
  • DECLARE-LONG II: A Prospective Randomized Trial of Triple vs. Dual Antiplatelet Therapy to Reduce Restenosis in Long Coronary Lesions Treated with Zotarolimus-Eluting Stents
  • DK-CRUSH-II: A Prospective Randomized Trial of Double Kissing Crush Stenting Compared to Provisional Stenting for Treatment of True Coronary Bifurcation Lesions
  • TRIAS High Risk: A Prospective Randomized Trial of Endothelial Progenitor Cell Capturing Stents Compared to Other Drug-Eluting Stents in Patients with Complex Coronary Artery Disease
  • ROMA: A Prospective Randomized Trial of Rosuvastatin Pretreatment Prior to Percutaneous Coronary Intervention
  • COMPARE-AMI: Two-Year Outcomes from a Prospective, Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with STEMI

WEDNESDAY, SEPTEMBER 22, 6:00 PM 8:00 PM

  • LEADERS: Three-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESSENCE-DIABETES: A Prospective Randomized Trial of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Diabetes Mellitus and Coronary Artery Disease
  • ZEST: Two-Year Outcomes from a Prospective, Randomized Trial of Sirolimus-Eluting Stents, Paclitaxel-Eluting Stents and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • APPOSITION II: A Prospective Randomized Trial of Self-Expanding vs. Balloon Expandable Stents in Patients with Acute Myocardial Infarction
  • CLOVIS-2: A Prospective, Randomized, Nested Case-Control Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • PRO-GR: A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • SOURCE TAVI Cohort 2: A Prospective Observational Study of More Than 2,300 Lower Risk and "Valve-in-Valve" Patients Undergoing Transcatheter Aortic Valve Implantation
  • PFO Closure: A Prospective Nonrandomized Propensity-Adjusted Study of PFO Closure Compared to Medical Therapy in Patients with Stroke Presumably Related to PFO

FRIDAY, SEPTEMBER 24, 6:00 PM 8:00 PM

  • LANCELOT CAD: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Coronary Artery Disease
  • MYTHOS: A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy
  • ODS-CAS: A Prospective Randomized Trial of Iso-Osmolar Contrast Compared to Low-Osmolar Contrast to Prevent Contrast Nephropathy in Patients Undergoing Carotid Artery Stenting
  • STEM CELL MOBILIZATION: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Granulocyte Colony Stimulating Factor After Acute Myocardial Infarction in Patients with Low Left Ventricular Ejection Fraction
  • PREVENT-ICARUS: A Prospective, Randomized, Double-Blind Trial of Intracoronary Adenosine to Prevent Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Angioplasty
  • CRYSTAL AMI: A Prospective Randomized Trial of Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • PEPCAD-CTO: A Prospective Nonrandomized Study of Paclitaxel-Eluting Balloons After Bare Metal Stent Placement in Successfully Recanalized Chronic Total Coronary Occlusions

Media may apply for registration by clicking on: http://www.tctconference.com/press/press-registration-form.html

Details on required press credentials can be found at: http://www.tctconference.com/press/press-credentials-a-guidelines.html

To view the program update, visit: http://www.tctconference.com/pdf/2010program-update.pdf

Receive updates on Twitter: http://twitter.com/TCTConference

View related video content on YouTube: http://www.youtube.com/user/TCTConference


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. Connecture, Inc. Announces Partnership with MedicareCRM
3. Chiquita Announces Support for School Salad Bar Campaign
4. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
5. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
6. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
7. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
10. Sunquest Announces Major Software Updates and Enhancements
11. Data Strategy Announces SurePath Services Offering for EMC Avamar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... Hospital M&A activity slowed in the second quarter of ... acquisitions rose to 23 in the second quarter, up 15% from the 20 publicly ... announced deals in the year-ago second quarter. Only four of the transactions disclosed a ...
(Date:7/21/2017)... ... ... The House of Yahweh in Abilene, Texas, has written a new post this week that ... to be more open about positive changes. Yisrayl says the use of force is not ... positive way to solve all; yes, all issues, and he is ready to share this ...
(Date:7/21/2017)... ... ... “Kids aren't born knowing how to regulate their emotions any more than ... St. Louis-based positive education company Generation Mindful. To help with that daunting task, she ... , The kit uses colorful, engaging and educational illustrations and games to teach children ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of ... FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts their ... rotating or flipping animation and can be changed using a drop-down menu. Create amazing ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
Breaking Medicine Technology: